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OBJECTIVE—Based on the premise that postabsorptive pa-
tients with type 1 diabetes receiving intravenous insulin in a dose
that maintains stable euglycemia are receiving biologically opti-
mal insulin replacement, we tested the hypothesis that glucagon
supports postabsorptive plasma glucose concentrations in
humans.
RESEARCH DESIGN AND METHODS—Fourteen patients
with type 1 diabetes were studied after an overnight fast on up to
ﬁve occasions. Insulin was infused intravenously to hold plasma
glucose concentrations at 100 mg/dl (5.6 mmol/l) overnight and
ﬁxed from 60 to 240 min the following morning. From 0 through
180 min the patients also received 1) saline, 2) octreotide 30 ng 
kg
1  min
1 with growth hormone replacement or octreotide
with growth hormone, plus 3) glucagon in doses of 0.5 ng  kg
1 
min
1, 4) 1.0 ng  kg
1  min
1, and 5) 2.0 ng  kg
1  min
1.
RESULTS—Compared with a mean  SE of 98  5 mg/dl (5.4 
0.3 mmol/l) at 180 min during saline, mean plasma glucose
concentrations declined to 58  1 mg/dl (3.2  0.1 mmol/l) (P 
0.001) at 180 min during octreotide plus saline and were 104  16
mg/dl (5.8  0.9 mmol/l) (NS), 143  13 mg/dl (7.9  0.7 mmol/l)
(P  0.004), and 160  15 mg/dl (8.9  0.8 mmol/l) (P  0.001)
at 180 min during octreotide plus glucagon in doses of 0.5, 1.0,
and 2.0 ng  kg
1  min
1, respectively.
CONCLUSIONS—In the setting of biologically optimal insulin
replacement, suppression of glucagon secretion with octreotide
caused a progressive fall in plasma glucose concentrations that
was prevented by glucagon replacement. These data document
that glucagon supports postabsorptive glucose concentrations in
humans. Diabetes 59:2941–2944, 2010
T
he current interest in the development of drugs
that block the action or secretion of glucagon for
the treatment of diabetes rests on the premise
that glucagon supports the plasma glucose con-
centration and, therefore, that glucagon, in concert with
insulin deﬁciency, may play a role in the pathogenesis of
hyperglycemia in diabetes (1–4). That premise is based
largely on studies with somatostatin including those with
the pancreatic clamp technique (4,5). That technique in-
volves infusion of somatostatin (or of the somatostatin
analog octreotide) (6), which suppresses insulin and glu-
cagon secretion among other actions, alone and with
insulin replacement, glucagon replacement, and both in-
sulin and glucagon replacement to document the roles of
suppression of those hormones in the changes in glycemia
(or in glucose kinetics when glucose concentrations are
clamped) that result from administration of somatostatin
(7–10).
Obviously, the biological appropriateness of the puta-
tive replacement doses of insulin and glucagon are critical
to the interpretation of pancreatic clamp data (11,12).
Excessive insulin replacement (or insufﬁcient glucagon
replacement) would confound the data. Insulin has been
infused peripherally in doses of 0.14 (13), 0.15 (7), 0.20
(14), and 0.24 (15) mU  kg
1  min
1 in humans to replace
basal insulin levels during infusion of somatostatin. How-
ever, we found that intravenous insulin doses as low as
0.15 mU  kg
1  min
1 are excessive; when infused alone
in healthy humans they drove plasma glucose concentra-
tions down to subnormal levels and thus activated glucose
counterregulatory systems (nearly complete suppression
of insulin secretion and stimulation of glucagon and
epinephrine secretion) (11). Although it also lowered
plasma glucose concentrations, insulin infused in a dose of
0.10 mU  kg
1  min
1 did not drive glucose down to
subnormal levels and therefore did not activate glucose
counterregulatory systems, at least over 2 h (11). Accord-
ingly, we used the latter lower insulin replacement dose in
additional pancreatic clamp studies in healthy adults (12).
Octreotide infusion caused plasma glucose concentrations
to decrease and then increase as expected (6–10); oct-
reotide plus insulin in a dose of 0.10 mU  kg
1  min
1
caused a sustained decrease in plasma glucose consistent
with the interpretation that glucagon, in concert with
insulin, supports the postabsorptive plasma glucose con-
centration. However, the addition of glucagon in a dose of
1.0 ng  kg
1  min
1, a putative replacement dose (16), to
octreotide and insulin did not raise glucose levels to those
observed during infusion of octreotide alone. Therefore,
the insulin dose was still too high, the glucagon dose was
too low, or both.
To clarify this issue, we tested the hypothesis that
glucagon supports the postabsorptive plasma glucose
concentration in insulin-sufﬁcient patients with type 1
diabetes. Our premise is that demonstrably endogenous
insulin-deﬁcient patients with type 1 diabetes infused
intravenously with insulin in a dose that maintains stable
euglycemia are receiving a biologically optimal insulin
replacement dose.
RESEARCH DESIGN AND METHODS
Fourteen patients with type 1 diabetes—ten women and four men with a
mean  SD age of 33  9 years, weight of 78  17 kg, BMI of 26.7  4.3 kg/m
2,
duration of diabetes of 16  11 years, and A1C of 7.8  0.8%—gave their
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Washington University Human Research Protection Ofﬁce and conducted at
the Washington University Clinical Research Unit (CRU). Six patients were
using a multiple daily injection insulin regimen with a long-acting insulin
analog as the basal insulin and a rapid-acting insulin analog as the prandial
insulin. Eight patients were using a continuous subcutaneous insulin infusion
regimen with a rapid acting insulin analog. With values less than the detection
unit of 0.1 ng/ml assigned that value, their mean  SD fasting plasma
C-peptide concentrations were 0.2  0.2 ng/dl (0.1  0.1 nmol/l).
Subjects were studied, after an overnight fast, on up to ﬁve occasions. They
took their last dose of long-acting insulin, if used, the morning of the day prior
to study and managed their diabetes with a rapid-acting insulin that day. They
reported to the CRU the evening prior to the study. An intravenous line was
inserted, and the plasma glucose concentration was held at 100 mg/dl (5.6
mmol/l) overnight with intravenous infusion of variable doses of regular
insulin (Novolin R; Novo Nordisk, Princeton, NJ). The following morning, that
insulin dose was adjusted, if necessary, and infused from 60 to 240 min.
Along with insulin, infused on all study occasions, initially the subjects
received intravenous 1) saline (n  14), 2) octreotide 30 ng  kg
1  min
1 (n 
14), 3) octreotide plus glucagon 1.0 ng  kg
1  min
1 (n  14), or 4) octreotide
plus glucagon 2.0 ng  kg
1  min
1 (n  10), in random sequence, from 0–180
min. After 10 studies, the glucagon dose of 2.0 ng  kg
1  min
1 was
discontinued and six patients received octreotide plus the glucagon dose of
0.5 ng  kg
1  min
1 from 0–180 min. Growth hormone (Genotropin;
Pharmacia and Upjohn, Kalamazoo, MI) was infused, in a dose of 4.7 ng  kg
1 
min
1 (15), along with octreotide. Glucose was infused intravenously, if
necessary to prevent plasma glucose concentrations 55 mg/dl (3.0 mmol/l).
Blood samples were drawn through an indwelling line in a hand, with that
hand kept in a 55°C plexiglas box to provide arterialized venous samples,
every 15 min for plasma glucose determinations and every 30 min for plasma
insulin, glucagon, growth hormone, and epinephrine and norepinephrine
measurements from 60 to 240 min. Blood pressure and heart rate were
recorded (Dash 3000; GE Healthcare, Fairﬁeld, CT) at 30-min intervals, and
the electrocardiogram was monitored throughout.
Analytical methods. Plasma glucose concentrations were measured with a
glucose oxidase method (YSI Glucose Analyzer; Yellow Springs Instruments,
Yellow Springs, OH). Plasma insulin, C-peptide, and growth hormone were
measured with two-site chemiluminescent assays (Immulite 1000; Siemens,
Los Angles, CA), plasma glucagon with the Linco radioimmunoassay (Milli-
pore, Temecula, CA), and plasma epinephrine and norepinephrine with a
single isotope derivative (radioenzymatic) method (17).
Statistical methods. Except where the SD is speciﬁed, data are reported as
the mean  SE. The time- and condition-related data were analyzed by
repeated-measures mixed model ANOVA. P values 0.05 were considered to
indicate statistically signiﬁcant differences.
RESULTS
Plasma glucose concentrations. Plasma glucose con-
centrations (Fig. 1A) were stable during saline infusion;
they were 101  3 mg/dl (5.6  0.2 mmol/l) at 0 min and
98  3 mg/dl (5.4  0.2 mmol/l) at 180 min. Glucose levels
declined, from 102  3 mg/dl (5.7  0.2 mmol/l) to 58  1
mg/dl (3.2  0.1 mmol/l) (P vs. saline 0.001) during
octreotide infusion. Indeed, to prevent glucose levels 55
mg/dl (3.0 mmol/l), glucose was infused (0.9  0.2 mg 
kg
1  min
1) in the 3rd h in 10 of the 14 patients. Glucose
levels were stable during octreotide plus glucagon 0.5 ng 
kg
1  min
1 (98  2 mg/dl [5.4  0.1 mmol/l] to 104  15
mg/dl [5.8  0.9 mmol/l]), rose from 104  3 mg/dl (5.8 
0.2 mmol/l) to 143  13 mg/dl (7.9  0.7 mmol/l) (P vs.
saline  0.004) during octreotide plus glucagon 1.0 ng 
kg
1  min
1 and rose from 97  3 mg/dl (5.4  0.2 mmol/l)
to 160  15 mg/dl (8.9  0.8 mmol/l) (P vs. saline  0.001)
during octreotide plus glucagon 2.0 ng  kg
1  min
1. The
insulin infusion rates were 0.12  0.02, 0.14  0.02, 0.13 
0.02, 0.16  0.02, and 0.13  0.02 mU  kg
1  min
1,
respectively, in the ﬁve studies.
Plasma insulin and glucagon concentrations. Plasma
insulin concentrations (Fig. 1B) were stable (13  2 U/ml
[78  12 pmol/l] at 0 min and 12  2 U/ml [72  12
pmol/l] at 180 min) during saline infusion and the other
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FIG. 1. Mean  SE plasma glucose concentrations (A) and plasma insulin (B) and glucagon (C) concentrations in patients with type 1 diabetes
infused with insulin in doses that maintain euglycemia from 60 to 240 min with infusions of 1) saline (shaded area) (n  14), 2) octreotide (with
growth hormone replacement) (F)( n  14) (glucose was infused if necessary to prevent glucose levels <55 mg/dl [3.0 mmol/l]), 3) octreotide
(with growth hormone) plus glucagon 0.5 ng  kg
1  min
1 (E)( n  6), 4) plus glucagon 1.0 ng  kg
1  min
1 (Œ)( n  14), and 5) plus glucagon
2.0 ng  kg
1  min
1 (‚)( n  10). Oct., octreotide.
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1C) were also stable (50  3 pg/ml [14.4  0.9 pmol/l] at 0
min and 52  4 pg/ml [14.9  1.1 pmol/l[rsqb[ at 180 min)
during saline infusion. They decreased to 43  3 pg/ml
(12.3  0.9 pmol/l) during infusion of octreotide alone and
increased to 51  5 pg/ml (14.6  1.4 pmol/l), 105  10
pg/ml (30.1  2.9 pmol/l), and 166  19 pg/ml (47.7  5.5
pmol/l) during infusion of octreotide plus glucagon in
doses of 0.5, 1.0, and 2.0 ng  kg
1  min
1, respectively.
Other data. Because growth hormone was infused,
plasma growth hormone concentrations were stable dur-
ing all octreotide infusions (e.g., 2.2  0.6 ng/ml [97  26
pmol/l] at 0 min and 1.7  0.2 ng/ml [75  9 pmol/l] at 180
min during octreotide with growth hormone without glu-
cagon replacement). Plasma epinephrine concentrations
tended to increase when plasma glucose levels fell during
infusion of octreotide with growth hormone without glu-
cagon replacement (data not shown). Heart rate, systolic
blood pressure, and diastolic blood pressure were similar
under the ﬁve study conditions (data not shown).
DISCUSSION
The optimal insulin replacement dose during pancreatic
clamps in humans remains to be determined (11,12). There
is evidence that insulin doses of 0.14–0.24 mU  kg
1 
min
1, used earlier (7,13–15), are excessive; indeed, an
insulin dose of 0.10 mU  kg
1  min
1 lowered plasma
glucose concentration in healthy humans (11). When that
dose was infused with octreotide, the addition of a puta-
tive replacement dose (16) of glucagon did not recreate
the glycemic pattern observed during infusion of oct-
reotide alone (12). The latter ﬁnding suggests that the
insulin dose was still too high, the glucagon dose was too
low, or both. The biologically optimal insulin replacement
dose would be one that maintains euglycemia in the
absence of endogenous insulin secretion. That condition is
met in patients with type 1 diabetes, who have virtually no
endogenous insulin secretion, receiving infusions of insu-
lin in doses that maintain stable euglycemia over time.
In such patients receiving biologically optimal insulin
replacement in ﬁxed doses, we tested the hypothesis that
glucagon supports the postabsorptive plasma glucose con-
centration by comparing the plasma glucose concentra-
tions during saline infusion with those during infusion of
the somatostatin analog octreotide (with growth hormone
replacement) alone and with three doses of glucagon.
During infusion of saline, plasma glucose levels were
stable. During infusion of octreotide without glucagon,
plasma glucose levels declined progressively to subnormal
levels. Indeed, glucose infusions were required to prevent
glucose levels 55 mg/dl (3.0 mol/l) in 10 of the 14
patients. Remarkably, that decline in plasma glucose was
prevented, and euglycemia was maintained, by coinfusion
of only 0.5 ng  kg
1  min
1 of glucagon with octreotide.
The latter ﬁnding provides additional evidence that such
low glucagon doses are biologically active (4,16,18,19).
Thus, these data indicate that even the lower insulin dose
used in our previous pancreatic clamp study (12) was still
too high and that the glucagon dose was not too low. They
convincingly conﬁrm that glucagon supports the postab-
sorptive plasma glucose concentration in humans. Indeed,
the glycemic response to the lowest dose of glucagon and
the hyperglycemic responses to the higher doses suggest a
substantial impact of glucagon.
Limitations of the present study include the fact that
although four limbs—saline, octreotide without glucagon,
octreotide plus glucagon 1.0 ng  kg
1  min
1, and
octreotide plus glucagon 2.0 ng  kg
1  min
1—were
conducted in random sequence, the octreotide plus gluca-
gon 0.5 ng  kg
1  min
1 limb was performed toward the
end of the study in a subset of the patients. In addition, the
glucagon radioimmunoassay that was used cross-reacts
with molecular species in addition to 3,500 Da glucagon
(4,5). Thus, despite clear effects on plasma glucose con-
centrations, the decrement in measured plasma glucagon
during infusion of octreotide and the increment during
infusion of octreotide with the lowest dose of glucagon
were small. Finally, other neuroendocrine and cardiovas-
cular effects of octreotide were not studied. However,
complete reversal of the glucose lowering effect of oct-
reotide by coinfusion of a relatively low dose of glucagon
suggests that these other effects play little, if any, role in
the changes in plasma glucose levels.
Interestingly, the insulin infusion doses that maintained
euglycemia in these patients were slightly greater than
0.10 mU  kg
1  min
1, a dose we used earlier (12) and
now judge excessive in nondiabetic individuals. However,
patients with type 1 diabetes are known to be somewhat
resistant to the actions of insulin (20–22).
These data document that glucagon, in concert with
insulin, supports the postabsorptive plasma glucose con-
centrations in humans. Thus, they support the notion that
glucagon, in concert with insulin deﬁciency, plays a role in
the pathogenesis of hyperglycemia in diabetes (1–4) and
the interest in the development of drugs that block the
action or secretion of glucagon for the treatment of
diabetes (4).
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